about
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiPrognosis of screen-detected breast cancers: results of a population based studyCancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003.Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraEnteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project.Classic Kaposi's sarcoma in Italy, 1985-1998Pattern of cancer risk in persons with AIDS in Italy in the HAART era.Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo ItalR-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repairEffectiveness of service screening: a case-control study to assess breast cancer mortality reduction.Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility.What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study.Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate.Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy).The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study.Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy.A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy.The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.
P50
Q28273184-01D88DED-44A5-4858-B5D9-51E1A0972AB5Q33232320-1A852B5B-FDE5-4DE9-B042-00C0757B2957Q33261614-8BD18535-59C8-459A-960A-10EFA1919F71Q33311606-88F4855D-1626-4DC0-87E3-2C6665B2C231Q33345685-8477DEAE-33F5-49C1-909B-C538B30CB4A5Q33391919-BAC0912A-E862-4CDA-A50A-E834ACC45D1CQ33393849-BA0AA28F-9BCE-4F02-B05B-7EE83285CC7EQ33558130-EE7213E6-1721-4935-ACCD-5082108BD5A3Q34184665-47B99421-81FF-43AD-8BEF-BCBC7731102FQ34552954-78C89164-F34B-406F-85DD-30C9DAFBA24DQ34604639-C6289205-11ED-456B-A00F-DE843D3DFB12Q35195231-ACBF9BFE-22AD-499D-8DEF-3CD0119E787FQ35574807-FF56E691-721B-42B6-8647-3939180439F6Q36858064-F66B2DC0-3317-4074-B8B4-C723D3AD02C7Q37306835-482E87E1-997D-4110-9ACB-C48B78AC4764Q37877039-EDF7E6AB-F222-4A4A-831C-85FED1C27DB5Q37966305-216A6223-3B7B-4B03-987D-0805B0EC06B8Q38122437-66670D16-A3D2-433A-9CC8-B325E22057B6Q38417399-8CF7D074-773A-41EE-BF28-5635AB02F40EQ38426380-E7F10701-448E-4A2F-BE9B-C86D406B9CD1Q39336799-5A2C9FEB-DA0B-485C-BCDF-E437B07108D5Q39500972-79E05A90-2DCA-49F5-872A-B2643384A9F9Q39986126-EB5D2C65-AA61-4C3C-A6B3-481037A7E1EAQ40088524-608E4175-0A07-48EC-B046-76BE28026BA6Q40152757-C5C72C59-9F57-499B-A528-A9B98485B722Q43199533-AD256DB1-C2D2-4B15-8666-E752248E3EB9Q43206344-1DDC61A4-2B9A-44FA-A4F6-1C4C5CA3732FQ43232777-FDD82330-7E58-4D10-90A7-6C01DC1E4758Q43508231-AAD4F7FA-5023-48FA-804E-68E98514E7E6Q43790629-8FABB410-BE63-4F08-B71F-408C929CA4A2Q43935919-CFBA57F4-DC1B-4453-A651-AA1669D6EAEDQ43988002-DBB155C7-6C3B-475A-AFC7-506148B72F09Q44038782-824D7B1F-3083-443E-A228-640C24F71D93Q44405230-E7D4437A-A843-4EA5-A46E-6ADAF636F1E1Q44447816-60237671-DFD0-461A-B9AA-1C32F56A6A57Q44477265-1050DD9B-8DC7-4C0B-BBF6-5F884EAC3400Q44585972-199CA56F-661C-4BB1-8EC1-850E410EE2D4Q44592953-063709E2-8494-4CB0-B135-96965588D216Q44803655-2882B7BE-223E-4474-8136-088FEF75960EQ44939805-BB095D4D-D990-4AFB-8A30-0C9C933555EA
P50
description
researcher ORCID ID = 0000-0002-5074-3262
@en
name
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
type
label
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
prefLabel
Massimo Federico
@ast
Massimo Federico
@en
Massimo Federico
@es
Massimo Federico
@nl
P106
P21
P31
P496
0000-0002-5074-3262